Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancer.
Nanobody
PSA
PSMA
Prostate cancer
VHH
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
30 Oct 2021
30 Oct 2021
Historique:
received:
23
07
2021
accepted:
21
10
2021
entrez:
31
10
2021
pubmed:
1
11
2021
medline:
1
11
2021
Statut:
epublish
Résumé
Prostate cancer is one of the most common cancers in men and its incidence has increased dramatically in the last decade. This increase in the detection of this type of cancer is based more on the detection of PSA or PSMA antigens as the most important specific antigens of this cancer, and this early detection has greatly helped in the more optimal treatment of patients. Many methods have been proposed by researchers for early detection of prostate cancer, but most of the methods used today to detect this type of cancer have been using classical antibodies. Although classical antibodies are able to detect tumor cell markers, but instability, large size, costly and laborious production, and random immobility characteristics, causes many problems. Nanobodies or VHHs, which are derived from camel heavy chain antibodies, have special advantages and have eliminated the disadvantages of classical antibodies which makes them attractive to use in biosensors and cancer diagnostic kits. The research that has been done so far shows that the introduced nanobodies are created for the purpose of targeting, detecting and sensing prostate cancer cells with two main purposes. The first is the efficient identification of prostate cancer and the second is the elimination of cancer cells. Research shows the use of specific nanobodies against prostate cancer antigens in the design of biosensors and target therapy will be very interesting. In this review article, these nanobodies are introduced and categorized based on their performance.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer is one of the most common cancers in men and its incidence has increased dramatically in the last decade. This increase in the detection of this type of cancer is based more on the detection of PSA or PSMA antigens as the most important specific antigens of this cancer, and this early detection has greatly helped in the more optimal treatment of patients.
MAIN BODY
METHODS
Many methods have been proposed by researchers for early detection of prostate cancer, but most of the methods used today to detect this type of cancer have been using classical antibodies. Although classical antibodies are able to detect tumor cell markers, but instability, large size, costly and laborious production, and random immobility characteristics, causes many problems. Nanobodies or VHHs, which are derived from camel heavy chain antibodies, have special advantages and have eliminated the disadvantages of classical antibodies which makes them attractive to use in biosensors and cancer diagnostic kits. The research that has been done so far shows that the introduced nanobodies are created for the purpose of targeting, detecting and sensing prostate cancer cells with two main purposes. The first is the efficient identification of prostate cancer and the second is the elimination of cancer cells.
CONCLUSION
CONCLUSIONS
Research shows the use of specific nanobodies against prostate cancer antigens in the design of biosensors and target therapy will be very interesting. In this review article, these nanobodies are introduced and categorized based on their performance.
Identifiants
pubmed: 34717636
doi: 10.1186/s12935-021-02285-0
pii: 10.1186/s12935-021-02285-0
pmc: PMC8557569
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
580Informations de copyright
© 2021. The Author(s).
Références
J Biol Chem. 2004 Dec 10;279(50):51965-72
pubmed: 15459193
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Biol Markers. 2014 Jun 25;29(2):e169-79
pubmed: 24425321
Appl Microbiol Biotechnol. 2013 May;97(10):4457-66
pubmed: 23135228
Anal Chem. 2005 Dec 1;77(23):7547-55
pubmed: 16316161
Cancer Biother Radiopharm. 2017 Mar;32(2):67-73
pubmed: 28301262
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339-1350
pubmed: 33094433
Immunol Invest. 2009;38(2):165-80
pubmed: 19330625
Lancet Oncol. 2014 Oct;15(11):e484-92
pubmed: 25281467
DNA Cell Biol. 2012 Jun;31(6):1015-26
pubmed: 22277093
Mol Biotechnol. 2013 Oct;55(2):159-67
pubmed: 23666874
J Med Chem. 2020 Jul 23;63(14):7601-7615
pubmed: 32442375
Biomater Sci. 2021 Jan 5;9(1):133-147
pubmed: 33135714
Hybridoma (Larchmt). 2012 Dec;31(6):424-9
pubmed: 23244321
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Contrast Media Mol Imaging. 2014 May-Jun;9(3):211-20
pubmed: 24700748
J Immunol Methods. 2009 Oct 31;350(1-2):54-62
pubmed: 19744487
PLoS One. 2015 Jun 25;10(6):e0127419
pubmed: 26111008
Protein Sci. 2002 Mar;11(3):500-15
pubmed: 11847273
J Nucl Med. 2015 Jul;56(7):1094-9
pubmed: 25977460
J Pharm Biomed Anal. 2018 Sep 5;158:361-369
pubmed: 29935325
J Cell Biochem. 2019 Jun;120(6):10787-10795
pubmed: 30672018
Life Sci. 2020 Sep 15;257:118052
pubmed: 32634431
Biosens Bioelectron. 2005 Sep 15;21(3):483-90
pubmed: 16076438
Appl Environ Microbiol. 2005 Jan;71(1):442-50
pubmed: 15640220
J Immunol Methods. 2007 Jul 31;324(1-2):13-25
pubmed: 17568607
Biotechnol Appl Biochem. 2021 Apr;68(2):239-246
pubmed: 32270531
Appl Microbiol Biotechnol. 2006 Sep;72(3):544-51
pubmed: 16450109